StockData
Nasus Pharma Ltd logo

Nasus Pharma Ltd (NSRX) stock

NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30
$2.70+0.09 (+3.45%)

Close on Nov 18, 2026Market cap $24.34MP/E –Yield –

Nasus Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$4.90M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.90M–
FY2024Dec 31, 2024-$1.08M–
FY2023Dec 31, 2023-$1.15M–

More Nasus Pharma figures

See a number that looks wrong?